SOLID TUMORS (PHASE 1)
Clinical trials for SOLID TUMORS (PHASE 1) explained in plain language.
Never miss a new study
Get alerted when new SOLID TUMORS (PHASE 1) trials appear
Sign up with your email to follow new studies for SOLID TUMORS (PHASE 1), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill targets Hard-to-Treat cancers with RAS gene flaw
Disease control Recruiting nowThis early-phase study tests an experimental pill, AN9025, in adults with advanced solid tumors that have a specific genetic change called a RAS mutation. The main goal is to find a safe dose and check for side effects. About 118 participants will take the drug daily or weekly an…
Matched conditions: SOLID TUMORS (PHASE 1)
Phase: PHASE1 • Sponsor: Adlai Nortye Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New Antibody-Drug conjugate enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called ADCE-B05 in 180 people with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to …
Matched conditions: SOLID TUMORS (PHASE 1)
Phase: PHASE1 • Sponsor: Adcendo ApS • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New pill targets Hard-to-Treat cancers in early human trial
Disease control Recruiting nowThis early-stage trial is testing an experimental oral drug called HSK42360-Na in 159 adults with advanced solid tumors that have a specific genetic change (BRAF V600 mutation). The main goals are to find a safe dose and check for side effects. Researchers will also watch for any…
Matched conditions: SOLID TUMORS (PHASE 1)
Phase: PHASE1 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New oral drug targets Hard-to-Treat cancers with missing gene
Disease control Recruiting nowThis early-stage trial tests an experimental oral drug called ABSK131 in people with advanced solid tumors that have lost a gene called MTAP. The study aims to find a safe dose and see if the drug can shrink tumors. About 266 participants will receive the drug daily, and research…
Matched conditions: SOLID TUMORS (PHASE 1)
Phase: PHASE1 • Sponsor: Abbisko Therapeutics Co, Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC